Positive News SentimentPositive NewsNASDAQ:AMLX Amylyx Pharmaceuticals (AMLX) Stock Price, News & Analysis → Bigger Than NVIDIA? (From Behind the Markets) (Ad) Free AMLX Stock Alerts $1.63 -0.02 (-1.21%) (As of 09:27 AM ET) Add Compare Share Share Today's Range$1.62▼$1.6450-Day Range$1.64▼$2.6752-Week Range$1.58▼$25.48Volume20,198 shsAverage Volume2.37 million shsMarket Capitalization$110.86 millionP/E RatioN/ADividend YieldN/APrice Target$28.67 Stock AnalysisStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrendsStock AnalysisAnalyst ForecastsChartCompetitorsEarningsFinancialsHeadlinesInsider TradesOptions ChainOwnershipSEC FilingsShort InterestTrends Get Amylyx Pharmaceuticals alerts: Email Address Amylyx Pharmaceuticals MarketRank™ Stock AnalysisAnalyst RatingHold2.25 Rating ScoreUpside/Downside1,637.4% Upside$28.67 Price TargetShort InterestHealthy16.50% of Float Sold ShortDividend StrengthN/ASustainabilityN/ANews Sentiment1.53Based on 5 Articles This WeekInsider TradingSelling Shares$19,655 Sold Last QuarterProj. Earnings GrowthGrowingFrom ($1.36) to ($1.17) Per ShareSee Full Details Hide Full Details Overall MarketRank™New Rank-Based ScoringMarketRank™ is calculated by averaging available category scores (with extra weight given to analysis and valuation), then ranking the company's weighted average against that of other companies.3.40 out of 5 starsMedical Sector281st out of 913 stocksPharmaceutical Preparations Industry124th out of 430 stocks 3.1 Analyst's Opinion Consensus RatingAmylyx Pharmaceuticals has received a consensus rating of Hold. The company's average rating score is 2.25, and is based on 2 buy ratings, 6 hold ratings, and no sell ratings.Amount of Analyst CoverageAmylyx Pharmaceuticals has only been the subject of 2 research reports in the past 90 days.Read more about Amylyx Pharmaceuticals' stock forecast and price target. Previous Next 4.0 Short Interest Percentage of Shares Shorted16.50% of the float of Amylyx Pharmaceuticals has been sold short.Short Interest Ratio / Days to CoverAmylyx Pharmaceuticals has a short interest ratio ("days to cover") of 3.2, which is generally considered an acceptable ratio of short interest to trading volume.Change versus previous monthShort interest in Amylyx Pharmaceuticals has recently decreased by 5.26%, indicating that investor sentiment is improving significantly. Previous Next 0.0 Dividend Strength Dividend YieldAmylyx Pharmaceuticals does not currently pay a dividend.Dividend GrowthAmylyx Pharmaceuticals does not have a long track record of dividend growth. Previous Next N/A Sustainability and ESG Overall ESG (Environmental, Social, and Governance) ScoreThere is no current Upright™ data available for AMLX. Previous Next 3.1 News and Social Media Coverage News SentimentAmylyx Pharmaceuticals has a news sentiment score of 1.53. This score is calculated as an average of sentiment of articles about the company over the last seven days and ranges from 2 (good news) to -2 (bad news). This is a higher news sentiment than the 0.91 average news sentiment score of Medical companies.News Coverage This WeekMarketBeat has tracked 5 news articles for Amylyx Pharmaceuticals this week, compared to 6 articles on an average week.Search InterestOnly 7 people have searched for AMLX on MarketBeat in the last 30 days. This is a decrease of -71% compared to the previous 30 days.MarketBeat Follows6 people have added Amylyx Pharmaceuticals to their MarketBeat watchlist in the last 30 days. This is an increase of 200% compared to the previous 30 days. Previous Next 4.2 Company Ownership Insider Buying vs. Insider SellingIn the past three months, Amylyx Pharmaceuticals insiders have sold 278.13% more of their company's stock than they have bought. Specifically, they have bought $5,198.00 in company stock and sold $19,655.00 in company stock.Percentage Held by Insiders11.70% of the stock of Amylyx Pharmaceuticals is held by insiders. A high percentage of insider ownership can be a sign of company health.Percentage Held by Institutions95.84% of the stock of Amylyx Pharmaceuticals is held by institutions. High institutional ownership can be a signal of strong market trust in this company.Read more about Amylyx Pharmaceuticals' insider trading history. Previous Next 1.3 Earnings and Valuation Earnings GrowthEarnings for Amylyx Pharmaceuticals are expected to grow in the coming year, from ($1.36) to ($1.17) per share.Price to Earnings Ratio vs. the MarketThe P/E ratio of Amylyx Pharmaceuticals is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Earnings Ratio vs. SectorThe P/E ratio of Amylyx Pharmaceuticals is -1.54, which means that its earnings are negative and its P/E ratio cannot be compared to companies with positive earnings.Price to Book Value per Share RatioAmylyx Pharmaceuticals has a P/B Ratio of 0.26. P/B Ratios below 1 indicate that a company could be undervalued with respect to its assets and liabilities.Read more about Amylyx Pharmaceuticals' valuation and earnings. Previous Next See Top Rated MarketRank™ Stocks Here Ad Prosper Trading Academywhy 99.94% won’t make you moneyI believe there's only 5-7 stocks that you should trade in 2024. But here's the catch…because there's always a catch in life. You NEED to use a specific system when you trade them.Click here to download my options trading cheat sheet (5-7 stocks inside here) About Amylyx Pharmaceuticals Stock (NASDAQ:AMLX)Amylyx Pharmaceuticals, Inc., a commercial-stage biotechnology company, engages in the discovery and development of treatment for amyotrophic lateral sclerosis (ALS) and neurodegenerative diseases. The company's products include RELYVRIO, a dual UPR-Bax apoptosis inhibitor composed of sodium phenylbutyrate and taurursodiol for the treatment of ALS in adults in the United States and marketed as ALBRIOZA for the treatment of ALS in Canada. It is also developing AMX0114 for other neurodegenerative diseases. Amylyx Pharmaceuticals, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.Read More AMLX Stock Price History View Price History Chart DataSkip Price History Chart 30 days | 90 days | 365 days | Advanced Chart AMLX Stock News HeadlinesJune 4, 2024 | businesswire.comAmylyx Pharmaceuticals to Present at the Goldman Sachs 45th Annual Global Healthcare ConferenceMay 13, 2024 | markets.businessinsider.comBank of America Securities Keeps Their Hold Rating on Amylyx Pharmaceuticals Inc (AMLX)May 10, 2024 | markets.businessinsider.comBuy Rating Affirmed for Amylyx Pharmaceuticals on Positive ALS and Wolfram Syndrome TrialsMay 10, 2024 | markets.businessinsider.comBreaking Down Amylyx Pharma: 9 Analysts Share Their ViewsMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) Q1 2024 Earnings Call TranscriptMay 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports Q1 2024 Financial ResultsMay 9, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Reports First Quarter 2024 Financial ResultsMay 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Present at the 2024 Bank of America Health Care ConferenceMay 2, 2024 | businesswire.comAmylyx Pharmaceuticals to Report First Quarter 2024 Financial Results on May 9, 2024April 17, 2024 | msn.comAmylyx Pharmaceuticals (AMLX) Price Target Decreased by 17.36% to 4.34April 12, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals: A Hold Rating Amidst Promising but Preliminary HELIOS Trial ResultsApril 11, 2024 | markets.businessinsider.comHold Rating on Amylyx Pharmaceuticals Amid Uncertainties in Drug Efficacy and Market ProspectsApril 10, 2024 | msn.comAmylyx Pharmaceuticals' Investigational Drug Shows Improved Pancreatic Function In Patients With Inherited DisorderApril 10, 2024 | finance.yahoo.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 10, 2024 | businesswire.comAmylyx Pharmaceuticals Announces Interim Data From Ongoing Phase 2 HELIOS Clinical Trial Demonstrating Improvements in Pancreatic Function and Glycemic Control with AMX0035 in People with Wolfram SyndromeApril 9, 2024 | prnewswire.comThe Gross Law Firm Notifies Amylyx Pharmaceuticals, Inc. Investors of a Class Action Lawsuit and Upcoming Deadline - AMLXApril 8, 2024 | markets.businessinsider.comOptimistic Outlook for Amylyx Pharmaceuticals Inc with AMX0035’s Potential in Rare DiseasesApril 8, 2024 | stockhouse.com48 HOUR DEADLINE ALERT: Faruqi & Faruqi, LLP Investigates Claims on Behalf of Investors of AmylyxApril 8, 2024 | businesswire.comThe Law Offices of Frank R. Cruz Reminds Investors of Looming Deadline in the Class Action Lawsuit Against Amylyx Pharmaceuticals, Inc. (AMLX)April 8, 2024 | businesswire.comAmylyx Pharmaceuticals to Host Virtual Webcast to Discuss Interim Data from Phase 2 HELIOS Study of AMX0035 in Wolfram Syndrome on April 10, 2024April 8, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals Shifts Focus: Hold Recommendation Amidst R&D Pivot and Revenue ImpactApril 8, 2024 | markets.businessinsider.comUnveiling 6 Analyst Insights On Amylyx PharmaApril 8, 2024 | prnewswire.comLevi & Korsinsky Announces the Filing of a Securities Class Action on Behalf of Amylyx Pharmaceuticals, Inc.(AMLX) ShareholdersApril 6, 2024 | finance.yahoo.comAnalysts Just Slashed Their Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) EPS NumbersApril 5, 2024 | markets.businessinsider.comAmylyx Pharmaceuticals (AMLX) Tanks 80% After RELYVRIO ALS Treatment Fails Phase 3, Follows Securities Class Action Complaint - Hagens BermanSee More Headlines Receive AMLX Stock News and Ratings via Email Sign-up to receive the latest news and ratings for Amylyx Pharmaceuticals and its competitors with MarketBeat's FREE daily newsletter. Email Address Company Calendar Last Earnings5/10/2024Today6/17/2024Next Earnings (Estimated)8/08/2024Fiscal Year End12/31/2024Get Stock AlertsIndustry, Sector and Symbol Stock ExchangeNASDAQ SectorMedical Industry Pharmaceutical preparations Sub-IndustryN/A Current SymbolNASDAQ:AMLX CUSIPN/A CIK1658551 Webamylyx.com Phone617-682-0917FaxN/AEmployees384Year FoundedN/APrice Target and Rating Average Stock Price Target$28.67 High Stock Price Target$48.00 Low Stock Price Target$3.00 Potential Upside/Downside+1,637.4%Consensus RatingHold Rating Score (0-4)2.25 Research Coverage8 Analysts Profitability EPS (Most Recent Fiscal Year)($1.07) Trailing P/E RatioN/A Forward P/E RatioN/A P/E GrowthN/ANet Income$49.27 million Net Margins-17.86% Pretax Margin-16.50% Return on Equity4.14% Return on Assets3.49% Debt Debt-to-Equity RatioN/A Current Ratio4.48 Quick Ratio4.48 Sales & Book Value Annual Sales$380.79 million Price / Sales0.29 Cash Flow$0.60 per share Price / Cash Flow2.74 Book Value$6.42 per share Price / Book0.26Miscellaneous Outstanding Shares68,010,000Free Float60,049,000Market Cap$112.22 million OptionableOptionable Beta-0.68 These 7 Stocks Will Be Magnificent in 2024With average gains of 150% since the start of 2023, now is the time to give these stocks a look and pump up your 2024 portfolio.Get This Free Report Key ExecutivesMr. Joshua B. Cohen (Age 32)Co-Founder, Co-CEO & Director Comp: $1.08MMr. Justin B. Klee (Age 33)Co-Founder, Co-CEO & Director Comp: $1.08MMr. James M. Frates M.B.A. (Age 57)Chief Financial Officer Comp: $763.16kMs. Gina M. Mazzariello (Age 53)Chief Legal Officer & General Counsel Comp: $689.26kDr. Camille L. Bedrosian M.D. (Age 71)Chief Medical Officer Comp: $232.6kMr. Tom HolmesChief Technical Operations OfficerLindsey AllenHead of Investor Relations & CommunicationsMs. Shauna HorvathHead of Global MarketingMs. Linda A. ArsenaultChief Human Resources OfficerMr. Chris AielloHead of Canada & GMMore ExecutivesKey CompetitorsAltimmuneNASDAQ:ALTIGM BiosciencesNASDAQ:IGMSAC ImmuneNASDAQ:ACIUALX OncologyNASDAQ:ALXOAcelyrinNASDAQ:SLRNView All CompetitorsInsiders & InstitutionsFarallon Capital Management LLCBought 1,150,221 shares on 5/24/2024Ownership: 1.691%Ikarian Capital LLCBought 186,400 shares on 5/17/2024Ownership: 0.000%Walleye Trading LLCBought 900 shares on 5/17/2024Ownership: 0.000%Price T Rowe Associates Inc. MDBought 75,775 shares on 5/15/2024Ownership: 1.427%Gina MazzarielloSold 10,455 sharesTotal: $19,655.40 ($1.88/share)View All Insider TransactionsView All Institutional Transactions AMLX Stock Analysis - Frequently Asked Questions Should I buy or sell Amylyx Pharmaceuticals stock right now? 8 Wall Street research analysts have issued "buy," "hold," and "sell" ratings for Amylyx Pharmaceuticals in the last twelve months. There are currently 6 hold ratings and 2 buy ratings for the stock. The consensus among Wall Street research analysts is that investors should "hold" AMLX shares. A hold rating indicates that analysts believe investors should maintain any existing positions they have in AMLX, but not buy additional shares or sell existing shares. View AMLX analyst ratings or view top-rated stocks. What is Amylyx Pharmaceuticals' stock price target for 2024? 8 brokerages have issued twelve-month price objectives for Amylyx Pharmaceuticals' stock. Their AMLX share price targets range from $3.00 to $48.00. On average, they anticipate the company's stock price to reach $28.67 in the next year. This suggests a possible upside of 1,637.4% from the stock's current price. View analysts price targets for AMLX or view top-rated stocks among Wall Street analysts. How have AMLX shares performed in 2024? Amylyx Pharmaceuticals' stock was trading at $14.72 at the start of the year. Since then, AMLX shares have decreased by 88.8% and is now trading at $1.65. View the best growth stocks for 2024 here. Are investors shorting Amylyx Pharmaceuticals? Amylyx Pharmaceuticals saw a decline in short interest during the month of May. As of May 31st, there was short interest totaling 7,570,000 shares, a decline of 5.3% from the May 15th total of 7,990,000 shares. Based on an average daily volume of 2,370,000 shares, the days-to-cover ratio is presently 3.2 days. Currently, 16.5% of the company's shares are short sold. View Amylyx Pharmaceuticals' Short Interest. When is Amylyx Pharmaceuticals' next earnings date? The company is scheduled to release its next quarterly earnings announcement on Thursday, August 8th 2024. View our AMLX earnings forecast. How were Amylyx Pharmaceuticals' earnings last quarter? Amylyx Pharmaceuticals, Inc. (NASDAQ:AMLX) released its earnings results on Friday, May, 10th. The company reported ($0.46) earnings per share for the quarter, missing the consensus estimate of $0.24 by $0.70. The firm earned $88.64 million during the quarter, compared to analyst estimates of $113.26 million. Amylyx Pharmaceuticals had a positive trailing twelve-month return on equity of 4.14% and a negative net margin of 17.86%. During the same quarter in the prior year, the business earned $0.02 EPS. What ETFs hold Amylyx Pharmaceuticals' stock? ETFs with the largest weight of Amylyx Pharmaceuticals (NASDAQ:AMLX) stock in their portfolio include SPDR S&P Pharmaceuticals ETF (XPH) and Direxion Daily Pharmaceutical & Medical Bull 3X Shares (PILL).iShares U.S. Pharmaceuticals ETF (IHE). When did Amylyx Pharmaceuticals IPO? Amylyx Pharmaceuticals (AMLX) raised $190 million in an initial public offering on Friday, January 7th 2022. The company issued 10,000,000 shares at $18.00-$20.00 per share. Who are Amylyx Pharmaceuticals' major shareholders? Amylyx Pharmaceuticals' stock is owned by a number of retail and institutional investors. Top institutional shareholders include Vanguard Group Inc. (7.86%), Farallon Capital Management LLC (1.69%), Price T Rowe Associates Inc. MD (1.43%), Ikarian Capital LLC (0.00%), Hennion & Walsh Asset Management Inc. (0.17%) and Swiss National Bank (0.13%). Insiders that own company stock include Daphne Quimi, George M Milne Jr, Gina Mazzariello, Global Investors Lp Viking, James M Frates, Joshua B Cohen, Justin B Klee, Morningside Venture Investment and Patrick D Yeramian. View institutional ownership trends. How do I buy shares of Amylyx Pharmaceuticals? Shares of AMLX stock can be purchased through any online brokerage account. Popular online brokerages with access to the U.S. stock market include Charles Schwab, E*TRADE, Fidelity, and Vanguard Brokerage Services. Compare Top Brokerages Here. This page (NASDAQ:AMLX) was last updated on 6/18/2024 by MarketBeat.com Staff From Our PartnersAI's Next Magnificent SevenThe Original Magnificent Seven Produced 16,894% Average Returns Over 20 Years.The Oxford Club | SponsoredBiden to Launch “FedNOW” [Move Your Money Now]Earlier this year President Biden signed the death warrant for America… Executive Order 14067 will essentia...Priority Gold | SponsoredBigger Than NVIDIA?With NVIDIA flying high, everyone is looking for the next breakout stock. But right now... There's only ...Behind the Markets | SponsoredBeta testers blew this thing upThis AI trading tool is probably unlike anything you've ever seen before… It scans the entire market and fi...Prosper Trading Academy | SponsoredRadical change coming — do this NOW to protect yourselfI recently uncovered a way the government could use the next crisis as a pretext to gain more control … and ra...Weiss Ratings | SponsoredThe attacks will come for me after releasing this…America’s “Internal Enemies” Exposed New documentary exposes a hidden election plan in Washington D.C. that...Porter & Company | SponsoredThe #1 Crypto That You Don’t Own… YetThere’s all kinds of “signals” to follow when investing in cryptos. But there’s one signal you should pay a...Crypto 101 Media | SponsoredMissed NVDA? Buy this AI stock NOWAfter Nvidia's record-breaking earnings surge, Wall Street is now selling the stock at the fastest pace in sev...Chaikin Analytics | Sponsored Adding Choose a watchlist: Watchlist Adding You have already added five stocks to your watchlist. Upgrade to MarketBeat All Access to add more stocks to your watchlist. Adding Amylyx Pharmaceuticals, Inc. Please log in to your account or sign up in order to add this asset to your watchlist. Share Amylyx Pharmaceuticals With A Colleague Link copied to clipboard. Get 30 Days of MarketBeat All Access for Free Sign up for MarketBeat All Access to gain access to MarketBeat's full suite of research tools. Start Your 30-Day Trial MarketBeat All Access Features Best-in-Class Portfolio Monitoring Get personalized stock ideas. Compare portfolio to indices. Check stock news, ratings, SEC filings, and more. Stock Ideas and Recommendations See daily stock ideas from top analysts. Receive short-term trading ideas from MarketBeat. Identify trending stocks on social media. Advanced Stock Screeners and Research Tools Use our seven stock screeners to find suitable stocks. Stay informed with MarketBeat's real-time news. Export data to Excel for personal analysis. Sign in to your free account to enjoy these benefits In-depth profiles and analysis for 20,000 public companies. Real-time analyst ratings, insider transactions, earnings data, and more. Our daily ratings and market update email newsletter. Sign in to your free account to enjoy all that MarketBeat has to offer. Sign In Create Account Your Email Address: Email Address Required Your Password: Password Required Log In or Sign in with Facebook Sign in with Google Forgot your password? Your Email Address: Please enter your email address. Please enter a valid email address Choose a Password: Please enter your password. Your password must be at least 8 characters long and contain at least 1 number, 1 letter, and 1 special character. Create My Account (Free) or Sign in with Facebook Sign in with Google By creating a free account, you agree to our terms of service. This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.